Dosing of Somatuline Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is available in three convenient
dosing strengths1

  • The recommended starting dose is 90 mg for the first three months*
  • No TID injections of a short-acting somatostatin analog are required for the first two weeks of therapy
  • After three months, the dose can be easily titrated using the following table:

Chart from Visual Aid

* Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline® Depot (lanreotide) Injection 60 mg.

 

How to inject Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is injected in an easy, two-step injection process.1 Learn more about injecting Somatuline® Depot (lanreotide) Injection.

 
 

Who should take Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation. It is also for patients who cannot tolerate surgery or radiation.1 Find out more about who should take Somatuline® Depot (lanreotide) Injection.

 
 

Support for patients taking Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is widely available, including through specialty pharmacies and is expected to be covered by most pharmacy benefit plans.2 Learn more about the reimbursement support for patients on Somatuline® Depot (lanreotide) Injection.